Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. - Concepedia

Concepedia

Publication | Closed Access

Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study.

314

Citations

0

References

1995

Year

C. Egsmose, B. Lund, G Borg, H. Pettersson, Einar Berg, Ulf Brodin, L Trang

Abstract

The results indicate the existence of a therapeutic window in RA within the first 2 years of the disease.